D. Boral Capital Reiterates “Buy” Rating for CorMedix (NASDAQ:CRMD)

CorMedix (NASDAQ:CRMD)‘s stock had its “buy” rating reissued by equities researchers at D. Boral Capital in a research note issued on Thursday,Benzinga reports. They currently have a $14.00 target price on the stock. D. Boral Capital’s target price would suggest a potential upside of 83.49% from the company’s current price.

CRMD has been the topic of several other reports. D Boral Capital raised CorMedix from a “hold” rating to a “strong-buy” rating in a research report on Monday, October 20th. Weiss Ratings restated a “hold (c)” rating on shares of CorMedix in a research note on Wednesday, October 8th. Zacks Research raised shares of CorMedix from a “hold” rating to a “strong-buy” rating in a report on Tuesday, November 4th. Royal Bank Of Canada reissued an “outperform” rating and set a $22.00 price objective (up from $21.00) on shares of CorMedix in a report on Tuesday, October 21st. Finally, Wall Street Zen cut shares of CorMedix from a “buy” rating to a “hold” rating in a report on Saturday, November 15th. Three research analysts have rated the stock with a Strong Buy rating, six have given a Buy rating and one has given a Hold rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus price target of $17.86.

CorMedix Trading Up 1.6%

Shares of NASDAQ CRMD opened at $7.63 on Thursday. The firm’s 50 day moving average price is $10.96 and its 200-day moving average price is $11.62. The company has a market cap of $601.17 million, a PE ratio of 3.70 and a beta of 1.36. CorMedix has a 52-week low of $5.60 and a 52-week high of $17.43. The company has a debt-to-equity ratio of 0.39, a quick ratio of 1.73 and a current ratio of 1.94.

CorMedix (NASDAQ:CRMD) last announced its quarterly earnings results on Wednesday, November 12th. The company reported $1.26 earnings per share for the quarter, beating the consensus estimate of $0.48 by $0.78. CorMedix had a net margin of 75.83% and a return on equity of 51.77%. The company had revenue of $104.28 million during the quarter, compared to the consensus estimate of $65.63 million. During the same quarter last year, the firm earned ($0.05) earnings per share. The firm’s quarterly revenue was up 810.2% compared to the same quarter last year. On average, equities research analysts expect that CorMedix will post -0.32 EPS for the current fiscal year.

Insider Buying and Selling at CorMedix

In other CorMedix news, Director Myron Kaplan purchased 25,000 shares of the company’s stock in a transaction dated Thursday, October 23rd. The shares were acquired at an average price of $11.02 per share, for a total transaction of $275,500.00. Following the purchase, the director directly owned 201,034 shares of the company’s stock, valued at $2,215,394.68. The trade was a 14.20% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Joseph Todisco sold 30,000 shares of the business’s stock in a transaction on Thursday, December 18th. The shares were sold at an average price of $12.00, for a total transaction of $360,000.00. Following the sale, the chief executive officer directly owned 509,496 shares of the company’s stock, valued at approximately $6,113,952. The trade was a 5.56% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders sold 90,000 shares of company stock worth $1,095,200. 3.10% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On CorMedix

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Deerfield Management Company L.P. bought a new stake in CorMedix during the third quarter valued at about $38,656,000. Marshall Wace LLP lifted its position in shares of CorMedix by 1,019.2% during the 2nd quarter. Marshall Wace LLP now owns 2,579,976 shares of the company’s stock valued at $31,785,000 after buying an additional 2,349,451 shares in the last quarter. UBS Group AG grew its stake in shares of CorMedix by 295.3% during the 3rd quarter. UBS Group AG now owns 1,090,908 shares of the company’s stock valued at $12,687,000 after acquiring an additional 814,964 shares during the period. Jump Financial LLC purchased a new stake in CorMedix in the 3rd quarter worth approximately $9,003,000. Finally, Raymond James Financial Inc. raised its stake in CorMedix by 646.8% during the 3rd quarter. Raymond James Financial Inc. now owns 651,987 shares of the company’s stock worth $7,583,000 after acquiring an additional 564,688 shares during the period. 34.18% of the stock is currently owned by hedge funds and other institutional investors.

Key Stories Impacting CorMedix

Here are the key news stories impacting CorMedix this week:

• Positive Sentiment: Analyst support remains: D. Boral Capital reaffirmed a “buy” rating with a $14 target, and Needham maintained a buy rating despite trimming its target from $16 to $15 — these endorsements help provide demand support for the shares. Analyst notes
• Positive Sentiment: Management continuity: CEO Joseph Todisco signed an extended employment contract and will add the Chairman role while the prior chair moves to Lead Independent Director — the move signals board-level continuity during the reset. Leadership update
• Neutral Sentiment: Investor outreach / visibility: Management will present a corporate overview at the J.P. Morgan Healthcare Conference (Jan 12), which could provide additional color and catalyze trading flows depending on guidance detail and Q&A. JPM presentation
• Neutral Sentiment: Valuation / bullish commentary: Coverage pieces (Zacks, Yahoo analysis) argue the stock may be undervalued or worth reassessing after the recent operational reset; these are watch items but not immediate catalysts. Zacks coverage
• Negative Sentiment: Material FY-2026 guidance reset: Management trimmed FY-2026 revenue guidance to $300–$320M versus consensus (~$445M), creating a large miss expectation and driving heavy selling pressure. Guidance cut article
• Negative Sentiment: Preliminary results and reduced outlook triggered downside: Q4/FY-2025 preliminary numbers were reported but the updated FY-2026 revenue range and related messaging prompted immediate negative investor reaction and headlines about a stock crash. Preliminary results
• Negative Sentiment: Reimbursement risk flagged: Analysis notes emerging CMS reimbursement headwinds that could pressure future revenue realization and margins — this is a structural risk that could sustain downward pressure if unresolved. CMS reimbursement analysis

CorMedix Company Profile

CorMedix Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to reduce inflammation and prevent infection in critically and chronically ill patient populations. The company’s lead product candidate, Neutrolin, is a catheter lock solution that combines taurolidine, heparin and citrate to prevent catheter-related bloodstream infections (CRBSIs) in patients undergoing hemodialysis. Neutrolin has received market authorization in the European Union under the CE Mark and is positioned to address a significant unmet medical need for infection prevention in dialysis centers.

In addition to its lead asset, CorMedix is advancing a biochemical portfolio aimed at mitigating complications associated with peritoneal dialysis and other high-risk procedures.